News
Press Releases
-
Aug 19, 2026
SanegeneBio Strengthens Pipeline Development and Strategy with Key Executive Appointments: Dr. Yuyan Jin and Dr. Jennifer Lockridge
-
May 19, 2026
SanegeneBio Receives NMPA Approval to Initiate a Clinical Trial of SGB-9768 for PNH and aHUS
-
Feb 24, 2026
SanegeneBio Announces FDA Orphan Drug Designation for SGB-9768 for the Treatment of IC-MPGN
-
Feb 2, 2026
SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
-
Jan 13, 2026
SanegeneBio Announces First Patient Dosed in Phase 1 Trial of SGB-7342
-
Dec 16, 2025
SanegeneBio Receives NMPA Approval to Initiate Clinical Trials of SGB-7342 for Obesity
-
Dec 8, 2025
SanegeneBio Raises over $110 Million in Series B Financing
-
Nov 14, 2025
SanegeneBio Announces Phase 1 Clinical Data for SGB-9768 Presented at ASN Kidney Week 2025
-
Nov 10, 2025
SanegeneBio and Innovent Announce Phase 1 Clinical Data for SGB-3908 Presented at American Heart Association (AHA) 2025 Annual Meeting
-
Nov 8, 2025
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly